• Colorectal disorders

Rowasa Generic Name & Formulations

General Description

Mesalamine 4g/60mL; enema; contains sulfites.

Pharmacological Class


How Supplied

Enema—7, 14, 28


Generic Availability


Rowasa Indications


Mild to moderate distal ulcerative colitis, proctosigmoiditis, proctitis.

Rowasa Dosage and Administration


4g (60mL) daily at bedtime for 3–6 weeks. Retain enema for 8 hours.


Not established.

Rowasa Contraindications

Not Applicable

Rowasa Boxed Warnings

Not Applicable

Rowasa Warnings/Precautions


Sulfite sensitivity. Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers.

Rowasa Pharmacokinetics


Fecal, renal.

Rowasa Interactions


Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results when measuring urinary normetanephrine; consider other alternative assay.

Rowasa Adverse Reactions

Adverse Reactions

Abdominal pain/cramps/discomfort, headache, flatulence, nausea, diarrhea, flu, malaise, fever, sore throat, dizziness, bloating, joint, back, or rectal pain, hemorrhoids, itching, constipation, hair loss, pancolitis, pericarditis, rash; renal impairment, acute intolerance syndrome, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).

Rowasa Clinical Trials

See Literature

Rowasa Note

Not Applicable

Rowasa Patient Counseling

See Literature